Besunyen Holdings Full Year 2022 Earnings: CN¥1.76 loss per share (vs CN¥3.65 loss in FY 2021)
Besunyen Holdings (HKG:926) Full Year 2022 Results
Key Financial Results
- Revenue: CN¥943.3m (down 14% from FY 2021).
- Net loss: CN¥99.1m (loss narrowed by 32% from FY 2021).
- CN¥1.76 loss per share (improved from CN¥3.65 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Besunyen Holdings shares are up 5.2% from a week ago.
You still need to take note of risks, for example - Besunyen Holdings has 3 warning signs (and 2 which don't sit too well with us) we think you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Besunyen Holdings is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Besunyen Holdings Company Limited engages in the research and development, production, and sale of therapeutic tea products and pharmaceuticals in the People's Republic of China.
Excellent balance sheet and slightly overvalued.